Pulmonary Fibrosis

HomePatientsLung Disease Week at the ATS2014Pulmonary Fibrosis ▶ Information for Experts
Information for Experts

Pulmonary Fibrosis Week

 

 

Know IPF Now

Sponsored by InterMune, the website offers patient-friendly facts about IPF pathophysiology, diagnosis, monitoring, and symptom management. Patients are provided with information to help maintain their lifestyle as long as possible by working in partnership with their healthcare team. The website also provides a directory of additional online patient resources. Learn more by visiting http://www.knowipfnow.com/.

IPF Rally

IPFRALLY.com, an online educational initiative sponsored by InterMune, is dedicated to supporting healthcare professionals in the management of patients with IPF. This informational website helps clinicians address the challenges of managing IPF through a variety of resources developed in collaboration with experts in the disease. For more information and to register online, visit http://www.ipfrally.com.

Clinician
ATS Educational Products

2014

A95 SKYFALL: LATE BREAKING CLINICAL TRIALS IN IDIOPATHIC PULMONARY FIBROSIS
B2 THE EVOLVING ROLE OF GENETICS IN THE CARE OF PULMONARY FIBROSIS

2013

A91 THERAPEUTIC STRATEGIES IN IDIOPATHIC PULMONARY FIBROSIS: DEBATES BETWEEN BENCH AND BEDSIDE: A PRO-CON DEBATE
D2 ADDING INSULT TO INJURY: COMPLICATIONS OF IDIOPATHIC PULMONARY FIBROSIS
D86 IMMUNE DYSREGULATION IN PULMONARY FIBROSIS

Clinician
ATS Journals on Pulmonary Fibrosis

 

American Journal of Respiratory and Critical Care Medicine

Pirfenidone for Idiopathic Pulmonary Fibrosis, Thrombocytosis in Chronic Obstructive Pulmonary Disease Exacerbations, and a Longitudinal Study on E-Cigarettes
Vol. 190, No. 6 (2014), pp. 699-700
Read Abstract

Wnt/β-Catenin and Transforming Growth Factor-β Signaling in Pulmonary Fibrosis. A Case for Antagonistic Pleiotropy?
Vol. 190, No. 2 (2014), pp. 129-131
Read Abstract

miR-31 Dysregulation in Cystic Fibrosis Airways Contributes to Increased Pulmonary Cathepsin S Production
Vol. 190, No. 2 (2014), pp. 165-174
Read Abstract

Distinct Differences in Gene Expression Patterns in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension
Vol. 190, No. 1 (2014), pp. 98-111
Read Abstract

 

American Journal of Respiratory Cell and Molecular Biology

Danger-Associated Molecular Patterns and Danger Signals in Idiopathic Pulmonary Fibrosis
Vol. 51, No. 2 (2014), pp. 163-168
Read Abstract

MicroRNA-326 Regulates Profibrotic Functions of Transforming Growth Factor-β in Pulmonary Fibrosis
Vol. 50, No. 5 (2014), pp. 882-892
Read Abstract  

Targeting Interleukin-13 with Tralokinumab Attenuates Lung Fibrosis and Epithelial Damage in a Humanized SCID Idiopathic Pulmonary Fibrosis Model
Vol. 50, No. 5 (2014), pp. 985-994
Read Abstract

Inhibition of Transglutaminase 2, a Novel Target for Pulmonary Fibrosis, by Two Small Electrophilic Molecules
Vol. 50, No. 4 (2014), pp. 737-747
Read Abstract  

 

Annals of ATS

Lung Microbiome Predicts Disease Progression in Idiopathic Pulmonary Fibrosis
Vol. 11, No. Supplement 1 (2014), pp. S79-S80
Read Abstract

Vitamin D Deficiency Is Associated with Pulmonary Exacerbations in Children with Cystic Fibrosis
Vol.11, No. 2 (2014), pp. 198-204
Read Abstract

Differential Responses to Rhinovirus- and Influenza-associated Pulmonary Exacerbations in Patients with Cystic Fibrosis
Vol. 11, No. 4 (2014), pp. 554-561
Read Abstract 

Perspective of a Daughter Turned Advocate
Read article here


Clinician
ATS Statements, Guidelines and Reports

ATS Statements, Guidelines and Reports are printed in the American Journal of Respiratory and Critical Care Medicine. These documents are also available in PDF format. You may download one copy of any ATS document; there is no charge for this service.

ATS Documents: Statements, Guidelines and Reports